Development of machine learning prognostic models for overall survival of epithelial ovarian cancer patients: a SEER-based study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Gradient Boosting Survival Analysis (GBSA) models accurately predict ovarian cancer survival, outperforming traditional Cox regression. This offers a valuable tool for informed clinical decision-making in epithelial ovarian cancer (EOC) prognosis.
Area Of Science
- Oncology
- Biostatistics
- Machine Learning in Healthcare
Background
- Epithelial ovarian cancer (EOC) survival prediction remains a challenge.
- Accurate prognostic models are crucial for guiding clinical decisions and patient management.
Purpose Of The Study
- To develop and compare machine learning (ML) models for predicting overall survival (OS) in EOC patients.
- To identify key prognostic factors influencing EOC patient outcomes.
Main Methods
- Utilized data from the SEER database (2004-2020) for 12,949 EOC patients.
- Developed and compared ML models including Random Survival Forest (RSF), Gradient Boosting Survival Analysis (GBSA), and Support Vector Machine (SVM) against Cox regression.
- Assessed model performance using AUC, concordance index (C-index), and Brier scores, with 5-fold cross-validation.
Main Results
- Identified 14 independent prognostic factors for OS in EOC.
- The GBSA model demonstrated superior predictive performance (AUC, C-index, Brier scores) compared to the Cox model.
- SHAP analysis highlighted FIGO stage, grade, and lymph node dissection as critical predictors in the GBSA model.
Conclusions
- The GBSA model offers enhanced accuracy for EOC survival prediction over traditional methods.
- This ML approach provides a valuable tool for clinicians to improve prognostic accuracy and inform treatment strategies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...